

### Remarks

Claims 61-80 are pending in this application. Claims 1-60 are canceled without prejudice to Applicants' right to pursue the subject matter recited by them in one or more divisional, continuation or continuation-in-part applications. Claims 61-82 are fully supported by the specification and claims as originally filed. Exemplary support for each pending claim is summarized in the table shown below. No new matter has been introduced.

Claim	Support	Claim	Support
61	Page 11, lines 23-25 Page 5, lines 18-24	62	Page 11, lines 23-25 Page 5, lines 18-24
63	Page 11, lines 23-25 Page 5, lines 18-24	64	Page 4, lines 35-37 Page 5, lines 18-24 Page 25, lines 23-31
65	Page 4, lines 35-37 Page 5, lines 18-24 Page 25, lines 23-31	66	Page 4, lines 35-37 Page 5, lines 18-24 Page 25, lines 23-31
67	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4	68	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 18, line 27 - page 19, line 2
69	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 18, lines 22-25	70	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 19, lines 15-16
71	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 19, lines 18-23	72	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 19, lines 18-29
73	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 19, lines 18-29, in particular, lines 24-25	74	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 18, lines 22-25 Page 22, lines 1-7


75	Page 3, lines 5-6 Claims 1-3 Page 5, lines 18-24 Page 19, lines 3-4 Page 18, lines 22-25 Page 22, lines 1-7, in particular, line 7	76	Page 8, lines 9-13 Page 5, lines 26-28 Page 8, lines 18-24
77	Page 8, lines 9-13 Page 5, lines 26-28 Page 8, lines 18-24 Page 17, lines 11-12	78	Page 8, lines 9-13 Page 5, lines 26-28 Page 8, lines 18-24 Page 17, line 14
79	Page 8, lines 9-13 Page 5, lines 26-28 Page 8, lines 18-24 Page 17, lines 14-15	80	Page 9, line 36 - page 10, line 3 Page 8, lines 18-24
81	Page 9, lines 31-35 Page 8, lines 18-24	82	Page 8, lines 9-13 and page 5, lines 26-28 (attention deficit disorder); page 9, lines 21-25 (obsessive-compulsive disorder); page 8, line 35 - page 9, line 3 (autism and schizophrenia); page 8, lines 17- 22 (obesity); page 10, lines 4-9 (anorexia and bulimia nervosa); page 9, lines 26-30 (cocaine and alcohol addiction); page 10, lines 14-20 (urinary incontinence); page 9, lines 16- 20 (pain); page 8, lines 26-32 (Parkinson's disease and epilepsy); and page 8, lines 18- 24

Pursuant to 37 C.F.R. § 1.604(b), Applicants note that new claims 61-82 define the same patentable invention as U.S. Patent No. 6,673,838 B2, which issued to Hadfield *et al.* on January 6, 2004. Applicants also direct the Examiner's attention to their co-pending application no. 10/720,134, filed November 25, 2003 ("the '134 application"). A supplemental preliminary amendment, which also presents claims to the same patentable invention as claimed in U.S. Patent No. 6,673,838 B2, is submitted concurrently herewith in the '134 application.

No fee is believed due for this submission. If any fees are required, however, please charge such fee(s) to Jones Day Deposit Account No. 503013.

Date March 23, 2004

Respectfully submitted,



45,479

Max Bachrach

Reg. No.

Jones Day

51 Louisiana Avenue, N.W.

Washington, DC 20001-2113

(202) 879-3939

*For:* Thomas E. Friebe (Reg. No. 29,258)

**Jones Day**

1155 Avenue of the Americas

New York, New York 10036

(212) 790-9090